Analystreport

Arcturus Therapeutics Ltd (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $26.00 price target on the stock.

Arcturus Therapeutics Holdings Inc.  (ARCT) 
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.arcturusrx.com/investor-relations